|drug1060||DigiVis visual acuity app Wiki||1.00|
|drug419||BMS-986337 Placebo Wiki||1.00|
|D014786||Vision Disorders NIH||0.71|
|D015354||Vision, Low NIH||0.71|
There is one clinical trial.
This trial aims to assess the accuracy and test-retest variability of a new digital app which enables community visual acuity testing without requirement of an trained examiner.
Description: Measurement bias in logMAR units between DigiVis testing and standard visual acuity testing score compared toMeasure: Comparison of visual acuity measurement using DigiVis testing and standard visual acuity testing Time: within 30 days
Description: Upper and lower levels of agreement measured in logMAR unitsMeasure: Levels of Agreement between DigiVis testing and standard visual acuity testing Time: within 30 days
Description: Measurement of test-retest variabilityMeasure: DigiVis test repeatability Time: within 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports